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osting by EAbstract With an ageing population and improved diagnostic modalities, the number of patients
with valvular heart disease is dramatically increasing. We are faced with more complex decisions in
patients with advanced age and increasing comorbidities. Advances in percutaneous valve interven-
tions – like percutaneous aortic valve replacement and mitral valve repair – have revolutionised the
way we manage such diseases. This overview highlights recent advances in the decision making –
process and the management of patients with valvular heart disease.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
With an ageing population and improved diagnostic modali-
ties, the number of patients with valvular heart disease is dra-
matically increasing. Considering projected changes in the age
distribution, a further accentuation of this trend can be
expected and this may indeed be considered ‘‘the next cardiac
epidemic’’.1 Obviously, we are faced with more complex deci-ation initiative involving all
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lseviersions in patients with advanced age and increasing comorbid-
ities. Advances in percutaneous valve interventional techniques
have entered into routine practice. At the same time, new data
on the natural history of disease and the identiﬁcation of pre-
dictors of outcome permit improvement in the decision-
making process and the management of patients with valvular
heart disease.
2. Aortic stenosis
2.1. Disease progression
In a population-based study which followed up 953 subjects
for 10 years, a high prevalence of calciﬁc aortic valve disease
(28%) associated with long-term exposure to raised cholesterol
levels and active smoking was described.2 Intraleaﬂet haemor-
rhage (detected by immunohistochemistry at the moment of
aortic valve replacement surgery) was frequently present in
the valve leaﬂets of degenerative aortic stenosis (AS) and was
associated with rapid progression of AS.3 In a small study of
164 patients with rheumatic AS (of whom 30 were treated with
a statin), progression of AS was slower in patients receiving
4 R. Rosenhekstatins than in untreated patients (annual change of peak aor-
tic velocity: 0.05 ± 0.07 m/s/year vs 0.12 ± 0.11 m/s/year,
p= 0.001).4 On the other hand in the ASTRONOMER trial,
a randomised double-blind study, that allocated 269 patients
to rosuvastatin 40 mg daily or to placebo, statin treatment
did not reduce progression of the disease in patients with AS.52.2. Predictors of outcome
Based on the aortic jet velocity and the B-type natriuretic pep-
tide (BNP) level, a risk score predicting outcome in patients
with moderate-to-severe asymptomatic AS was derived and
validated in an independent cohort: score = (peak velocity
(m/s) · 2) + (ln of BNP · 1.5) + 1.5 (if female sex). Event-free
survival after 20 months was particularly poor (7%) forpati-
ents in the fourth quartile.6 In a separate study of patients with
severe asymptomatic AS, event-free survival rates at 3 years
were 49%, 33% and 11% for patients with peak aortic jet
velocities between 4.0 and 5.0 m/s, 5.0 and 5.5 m/s or
>5.5 m/s, respectively. In addition to the important implica-
tions for risk stratiﬁcation, these data introduce us to the entity
of ‘‘very severe aortic stenosis’’ based on a peak aortic jet
velocity P5.0 m/s.7 In another study, receiver-operator curve
analysis identiﬁed a peak aortic jet velocity P4.4 m/s, a left
ventricular (LV) longitudinal myocardial deformation
65.9%, a valvular-arterial impedance P4.9 mm Hg/ml/m2
and an indexed left atrial areaP12.2 cm2/m2 as factors associ-
ated with adverse outcomes in 163 patients with moderate to
severe AS.8 Early elective surgery was performed on 102 pa-
tients with severe AS (valve area 60.75 cm2, AV-velocity
P4.5 m/s), and conventional treatment was used for 95 pa-
tients. Compared with conventional treatment, early surgery
in patients with very severe AS was associated with improved
long-term survival by decreasing cardiac mortality.9 However,
this was not a randomised study and selection bias might have
affected the results.
In asymptomatic patients with AS (n= 135) and a normal
exercise response, an exercise-induced increase in mean trans-
valvular gradient >20 mm Hg was described as an indepen-
dent risk predictor. These results thus suggest that exercise
stress echocardiography may provide prognostic information
additional to that obtained by standard exercise testing and
resting echocardiography.10 Symptoms on treadmill exercise
testing in 38 apparently asymptomatic patients with at least
moderate AS were associated with a lower peak myocardial
VO2, a lower peak stroke index during exercise and BNP
levels.11 Increased valvuloarterial impedance (Z(va)) (which
is calculated by dividing the estimated LV systolic pressure
(systolic arterial pressure + mean transvalvular gradient) by
the stroke volume indexed for the body surface area) is a mar-
ker of excessive LV haemodynamic load, and a value >3.5
successfully identiﬁed patients with AS with a poor outcome.12
However, the clinical value of this measure remains to be fully
determined.
The prognostic signiﬁcance of mid-wall ﬁbrosis and infarct
patterns detected by late gadolinium enhancement was evalu-
ated in 143 patients with aortic stenosis. Mid-wall ﬁbrosis
(HR= 5.35; p= 0.03) and ejection fraction (HR = 0.96;
p= 0.01) were independent predictors of all-cause mortality
and may provide an useful method of risk stratiﬁcation.13
There is evidence of subclinical myocardial dysfunction earlyin the disease process despite normal left ventricular ejection
fraction (LVEF). The myocardial dysfunction appears to start
in the subendocardium and to progress to transmural dysfunc-
tion with increasing AS severity. Symptomatic patients with
AS have more impaired multidirectional myocardial functions
than asymptomatic patients.14 In patients with severe AS, im-
paired multidirectional LV strain and strain rate are present
even with preserved LVEF, but a signiﬁcant improvement
occurs after aortic valve replacement (AVR).15 Lower average
longitudinal strain is related to higher LV mass, concentric
geometry and more severe AS.16 Inappropriately high LV mass
was found in 58% of asymptomatic patients with severe AS
and was related to cardiovascular events. Event-free survival
for patients with appropriate and inappropriate LV mass,
respectively, was 78% vs 56% at 1 year, 68% vs 29% at 3 years
and 56% vs 10% at 5 years (all p< 0.01).17 However, in
patients with calciﬁc AS and a normal LVEF the severity of
stenosis was the most important correlate of symptomatic
deterioration. Tissue Doppler measures of LV systolic and
diastolic function and LV mass provide limited predictive
information after accounting for the severity of stenosis.18
2.3. Outcome of symptomatic patients with aortic stenosis
Severe aortic valve stenosis is a medical condition with limited
short-term survival for patients over the age of 75 years, par-
ticularly those at high surgical risk. Patients with the highest
surgical risk have the worst prognosis if AS is not treated.19
It has been conﬁrmed, that patients screened but without the
inclusion/exclusion criteria necessary to participate in a
trans-catheter aortic valve implantation trial do poorly and
have extremely high mortality rates, especially in non-surgical
groups: 274 such patients were treated medically or with bal-
loon aortic valvuloplasty and had a mortality of 37.2% as
compared with a mortality of 21.5% for 88 patients who
underwent AVR (these latter patients were less symptomatic
and had a lower EURO-score) during a median follow-up of
about 1 year.20 In an observational study of 25 patients with
severe AS presenting in cardiogenic shock, the use of an
intra-aortic balloon pump improved the cardiac index from
1.77 to 2.18 and 2.36 l/min/m2 at 6 and 24 h, respectively
(p< 0.001) and should thus be considered in this critically ill
population while being evaluated for further interventions.21
2.4. Low gradient aortic stenosis
Five-year survival in patients with low-ﬂow/low-gradient aor-
tic stenosis without contractile reserve was higher in patients
undergoing AVR than in medically managed patients
(54 ± 7% vs 13 ± 7%, p= 0.001) despite a high operative
mortality of 22%. Surgery should thus not be withheld in this
subset of patients solely on the basis of lack of contractile
reserve on dobutamine stress echocardiography.22
Measuring the degree of aortic valve calciﬁcation by multi-
slice CT in patients with mild-to-moderate AS and an
EFP 40%, showed that a threshold of 1651 arbitrary units
provided 82% sensitivity, 80% speciﬁcity, 88% negative-pre-
dictive value and 70% positive-predictive value to diagnose se-
vere AS. Performance was best in a subset of patients with low
EF when the threshold correctly differentiated between
patients with severe AS (the diagnosis was conﬁrmed by mean
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phy) and those with non-severe AS in 46 of 49 cases. This
method may be particularly useful for the evaluation of AS
severity in difﬁcult cases, such as patients with reduced EF
and low or absent contractile reserve.23
On echocardiography approximately one-third of patients
with severe aortic valve stenosis, based on aortic valve area
<1.0 cm2, have a non-severe mean pressure gradient
(640 mm Hg) despite apparently normal left ventricular func-
tion. Three hundred and thirty-three consecutive patients
underwent cardiac catheterisation within 30 days after their
index echocardiography. On invasive testing, 85 patients
(26%) demonstrated inconsistent grading, with a signiﬁcantly
lower stroke volume and stroke volume index. However,
48% of inconsistently graded patients had a normal stroke
volume index >35 ml/m2. In the framework of current guide-
lines inconsistent grading of aortic valve stenosis is common,
extends to cardiac catheterisation and is only partially ex-
plained by low stroke volume despite apparently normal left
ventricular systolic function.24 In this SEAS substudy, aortic
valve-related events, major cardiovascular events and cardio-
vascular death in patients with low-gradient ‘‘severe’’ aortic
stenosis (aortic valve area <1.0 cm2 and mean gradient
640 mm Hg) were comparable to those of patients with mod-
erate stenosis (aortic valve area 1.0–1.5 cm2; mean gradient
25–40 mm Hg).25 These results fuel the debate on the manage-
ment of such patients. In severe AS, a low gradient is associ-
ated with a higher degree of interstitial ﬁbrosis in biopsy
samples and more late-enhancement MRI segments, decreased
longitudinal function assessed by echocardiography and
poorer clinical outcome despite preserved EF.26
2.5. Experimental studies in aortic stenosis
Higher serum phosphate levels within the normal range were
associated with aortic valve sclerosis and mitral and aortic
annular calciﬁcation in a community-based cohort of older
adults. In contrast, serum calcium, parathyroid hormone and
25-hydroxyvitamin D concentrations were not associated with
aortic or mitral calciﬁcation. Phosphate may be a new risk fac-
tor for calciﬁc aortic valve disease and warrants further
study.27 The upregulation of the leukotriene pathway in
human aortic valve stenosis and its correlation with clinical
stenosis severity, taken together with the potentially detrimen-
tal leucotriene-induced effects on valvular myoﬁbroblasts, sug-
gests one possible role of inﬂammation in the development of
AS.28 Mechanical properties of porcine aortic valve leaﬂets
were evaluated: serotonin induced a decrease in the areal stiff-
ness of the cusp, which was reversed by N-nitro-L-arginine-
methyl ester or endothelial denudation. Endothelin-1 caused
an increase in stiffness, but not in the presence of cytochalasin
B. Changes in cusp stiffness were accompanied by aortic cusp
relaxations to 5-hydroxytriptamine, which were reversed by
endothelial denudation and by N-nitro-L-arginine-methyl es-
ter. These data highlight the role of the endothelium in regulat-
ing the mechanical properties of aortic valve cusps and
underline the importance of valve cellular integrity for optimal
valve function.29 A reduced regenerative capacity of valvular
endothelial cells due to senescence and decreased levels of
endothelial progenitor cells might be, at least in part, a patho-
logical link for the destruction of valvular endothelial cells,resulting in the progression of degenerative AS.30 Direct
in vivo evidence was provided that cathepsin S-induced elastol-
ysis accelerates arterial and aortic valve calciﬁcation in chronic
renal disease, providing new insight into the pathophysiology
of cardiovascular calciﬁcation.31 In the low-density lipopro-
tein-receptor-deﬁcient mouse, regular exercise training pre-
vents aortic valve sclerosis by several mechanisms, including
the preservation of endothelial integrity, a reduction in inﬂam-
mation and oxidative stress, and inhibition of the osteogenic
pathway.32 Recombinant apolipoprotein A-I Milano treat-
ment reverses AS in an experimental rabbit model. The bene-
ﬁcial effects seem to be mediated by enhanced cholesterol
removal and by reduced inﬂammation and calciﬁcation.33
Additional data indicate that reducing plasma lipid levels by
genetic inactivation of the MTTP gene in hypercholesterolae-
mic mice with early aortic valve disease normalises oxidative
stress, reduces pro-osteogenic signalling and halts the progres-
sion of aortic valve stenosis.34 Patients with AS and diabetes
have worse diastolic LV dysfunction, predisposing to heart
failure. It appears to result from greater myocardial ﬁbrosis
(documented with perioperative LV biopsies), more intra-myo-
cardial vascular advanced glycation end-product deposition
and higher cardiomyocyte Fpassive, which is related to hypo-
phosphorylation of the N2B titin isoform.35
3. Aortic regurgitation
In an observational study of 756 patients with severe aortic
regurgitation (AR), those taking a b blocker (n= 355) had sig-
niﬁcantly better survival rates of 90% and 70% at 1- and 5-
years than patients not receiving treatment (75% and 55%,
respectively; p= 0.0009), suggesting that b-blocker treatment
may confer a survival beneﬁt in patients with severe AR.36
About one-quarter (191 of 756) of patients with severe AR
have at least moderate mitral regurgitation (MR), and in a ret-
rospective cohort study MR was an independent predictor of
reduced survival. Moreover, performing AVR plus concomi-
tant mitral valve repair was associated with improved survival.
These data suggest that the development of MR might provide
useful information about the timing of surgery in patients with
AR.37 Doctors are often reluctant to offer AVR to patients
with severe AR and associated severe LV dysfunction
(EF 6 35%), yet a recent study has shown that it results in sig-
niﬁcantly improved 5-year survival rates of 70% as compared
with 37% for patients not receiving surgery. Signiﬁcantly,
however, surgery was only performed in 53 of 166 patients.38
In patients with AR macroscopic LV hypertrophy normalises
late after AVR, although ﬁbre hypertrophy persists. These
changes in LV myocardial structure late after AVR are accom-
panied by a change in passive elastic properties with persistent
diastolic dysfunction.39
There is increasing interest in surgical reconstruction proce-
dures and in experienced hands, good early results have been
reported. Thus, in 316 patients who underwent reconstruction
of regurgitant bicuspid aortic valves hospital mortality was
63% and survival was 92% at 10 years. Freedom from reoper-
ation at 5 and 10 years was 88% and 81%, respectively. Predic-
tors of reoperation were age, aortoventricular diameter,
effective height, commissural orientation and the use of a peri-
cardial patch.40 In another study, an acceptable mid-term out-
come was reported for aortic valve-sparing surgery. Root
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remodelling (26%) technique. Cusp repair was required more
often in bicuspid valves than in tricuspid valves (91% vs
38%, p< 0.001). At 8 years, freedom from reoperation was
90 ± 7% and overall survival was 88 ± 8%. Predictors of
recurrent moderate or severe AR were preoperative left ven-
tricular end-diastolic diameter and more than mild AR on dis-
charge echocardiography.41
4. Bicuspid aortic valve disease
Cardiovascular magnetic resonance allows characterisation of
valve phenotype in patients with bicuspid aortic valves
(BAVs). A raphe was identiﬁed in the majority of patients
(n= 90; 86%). Among patients with raphe, 76 patients had fu-
sion between the right and left cusps and 14 patients had fusion
between the right and the non-coronary cusps.42 The fused
right and non-coronary leaﬂet BAVs are the product of a
morphogenetic defect that occurs before cardiac outﬂow tract
septation and probably relies on an exacerbated nitric oxide-
dependent epithelial-to-mesenchymal transformation. Fused
right and left leaﬂet BAVs result from anomalous septation
of the proximal portion of the cardiac outﬂow tract, probably
caused by the distorted behaviour of neural crest cells. The two
phenotypes are different aetiological entities and may rely on
different genotypes.43 The prevalence of aortic root dilation
in BAV patients is 32% and 53% in their ﬁrst-degree relatives
(even with tricuspid aortic valves). Like patients with BAV,
their ﬁrst-degree relatives have a signiﬁcantly lower aortic
distensibility and greater aortic stiffness index than control
subjects. Screening of ﬁrst-degree relatives of patients with a
bicuspid aortic valve by echocardiography should be consid-
ered for the detection of aortic valve malformation and dilated
ascending aorta.44 Careful clinical follow-up of patients after
successful resection of subaortic stenosis is required. Of 121
adults with subaortic stenosis, 23% had bicuspid valves and
21% had coarctation of the aorta. Seventy-nine per cent of
the patients had a surgical resection of subaortic tissue. Valve
surgery for AS was required in 26% and was more common in
patients with concomitant BAV disease, coarctation of the
aorta and supravalvular stenosis. Moderate to severe AR
was present in 16% of the patients.455. Aortic disease
Diastolic tenting of aortic leaﬂets is strongly related to the
severity of functional AR in patients with ascending thoracic
aortic aneurysms. A sinotubular junction/annulus mismatch
is signiﬁcantly associated with diastolic leaﬂet tenting and
valve regurgitation, independently of the aneurysm dimen-
sion.46 Aortic root dilatation and reduced aortic elasticity are
common in patients with tetralogy of Fallot, in addition to
minor degrees of AR and reduced left ventricular systolic func-
tion. Aortic wall pathology in patients with repaired tetralogy
of Fallot may therefore represent an independent contributor
to left ventricular dysfunction, as part of a multifactorial pro-
cess.47 In patients with ascending aortic aneurysm (unassoci-
ated with aortitis or acute dissection), the aortic valve is
congenitally malformed (unicuspid or bicuspid) in 98% of
patients with AS, and in 60% of patients with AR. Among
the patients with congenitally malformed valves, those withAR have a signiﬁcantly greater likelihood of signiﬁcant aortic
medial elastic ﬁbre loss than those with AS. Distinction be-
tween AS and AR is helpful in predicting loss of aortic medial
elastic ﬁbres in patients with ascending aortic aneurysms and
aortic valve disease.48 Ninety-three patients with severe iso-
lated calciﬁc AS with a tricuspid aortic valve who also had
moderate dilatation of the ascending aorta (diameter 50–
59 mm) underwent AVR only. During a follow-up of 15 years,
no acute aortic events (rupture, dissection, pseudoaneurysm),
or need for reoperation occurred. Furthermore, there was no
substantial increase in aortic dimensions, suggesting that
indications for concomitant aortic surgery in patients with
moderate post-stenotic dilatation of the ascending aorta and
a tricuspid aortic valve, may be viewed more leniently, partic-
ularly in the absence of connective tissue disorders.49 In a
community cohort that included 416 consecutive patients with
deﬁnite BAV diagnosed by echocardiography, followed up for
16 ± 7 years, the incidence of aortic dissection was low (2 out
of 416 patients) but higher than in the general population. Of
384 patients without baseline aneurysms, 49 developed aneu-
rysms at follow-up and the 25-year rate of aortic surgery was
25%.50
Prompt diagnosis of acute aortic dissection saves lives.
Echo-cardiography has a time-honoured role, and recent work
suggests that contrast-enhanced as compared with conven-
tional transthoracic imaging improves diagnostic sensitivity
and speciﬁcity for aortic dissection from 73.7% to 86.8%
(p< 0.005) and from 71.2% to 90.4% (p< 0.05), respectively.
Indeed, the diagnostic sensitivity and speciﬁcity of contrast-en-
hanced transthoracic imaging was similar to that of conven-
tional transoesophageal echocardiography in the ascending
aorta (93.3% vs 95.6% and 97.6% vs 96.4%, respectively)
and in the arch (88.4% vs 93.0% and 95.% vs 98.82%, respec-
tively) and should be considered as an initial imaging modality
in an emergency.516. Mitral regurgitation
Degenerative mitral regurgitation (MR) is often dynamic, and
exercise-induced increases of MR severity are seen in one-third
of the patients, associated with changes in systolic pulmonary
artery pressure and reduced symptom-free survival.52 When
MR is severe it may be associated with unilateral pulmonary
oedema.53
Improving the timing of surgery for degenerative MR based
on the predictors of outcome is an important topic. The left
atrial index was shown to predict outcome in 492 patients in
sinus rhythm with organic MR and should thus be incorpo-
rated into routine clinical practice for risk stratiﬁcation and
clinical decision-making.54 A recent study showed that in
MR, owing to ﬂail leaﬂets, a left ventricular end-systolic diam-
eter P40 mm is independently associated with increased
mortality for medically and surgically managed patients.
Nevertheless, the left ventricular end-systolic dimension may
provide an useful guide for the timing of surgery in these
patients but because both asymptomatic and symptomatic
patients were included, the ﬁndings need conﬁrmation in
symptomatically homogeneous cohorts.55 In another study of
256 patients with organic MR referred for mitral valve surgery,
baseline pulmonary artery systolic pressure predicted long-
term postoperative survival with 8-year survival rates of
Almanac 2011: Valvular heart disease 758.6% and 86.6% for patients whose PA pressures were great-
er or less than 50 mm Hg, respectively (p< 0.0001).56
As with other valvular pathologies, oxidative stress may be
aetiologically important in MR. Thus, LV biopsy specimens
taken during mitral valve repair surgery for isolated MR dem-
onstrated that increased oxidative stress could cause lipo-fus-
cin deposition and cardiomyocyte myoﬁbrillar degeneration.57
The severity of MR seems to be an important determinant
of left ventricular reverse remodelling after cardiac resynchro-
nisation therapy when gains in LVEF and forward stroke vol-
ume are the greatest for patients with improvement in total
MR, intermediate for those with mild or no MR at baseline
and least in those whose MR shows no improvement.58
Guideline indications for surgical intervention in patients
with MR are often ignored by cardiologists and in a recent
assessment of current practice, surgery was performed in only
about 50% of cases despite the fact that guideline indications
for intervention were present in many of the patients not
receiving surgery.59 Among patients with guideline indications
any delay in carrying out surgery may have important adverse
consequences as reﬂected in a recent report where surgery at a
median time of 0.42 months after listing was associated a lower
hazard for death than for those who underwent later surgery at
a median time of 8.75 months (HR = 0.54, p= 0.039).60
In the study of Samad et al. mitral valve repair was inde-
pendently associated with improved survival (HR= 0.45,
p= 0.01).60 This has been shown in many other recent stud-
ies but an assessment of ’real-world’ clinical practice based
on 12,255 mitral valve operations performed in the UK be-
tween 2004 and 2008 showed a national rate of only 51%,
and variability of 20% to 90% among different hospitals,
which the authors likened to a ‘‘lottery of mitral valve repair
surgery.’’61 This was emphasised further in a more recent
analysis of the STS Adult Cardiac Surgery Database, which
showed substantial variability in the rates of mitral valve re-
pair among individual surgeons, ranging from 0% to 100%
(mean 41%). The greatest variability in repair rates was seen
among surgeons carrying out a low volume of procedures,
with increased surgeon-level mitral volume being indepen-
dently associated with an increased probability of mitral
repair.627. Experimental studies on the mechanism of mitral
regurgitation
Understanding the mechanism of valve adaptation provides
potential means of identifying new biological and surgical ther-
apeutic targets. Anteroapical myocardial infarction (MI) with
inferoapical extension can mechanically displace papillary
muscles, causing MR despite the absence of basal and mid-
inferior wall motion abnormalities.63 In a sheep model of infe-
rior MI an epicardial patch to limit ventricular dilatation and
MR resulted in a leaﬂet area at 3 months that was not signif-
icantly different from baseline values. In untreated sheep, mi-
tral valve area increased over time as the left ventricular
remodelled after inferior MI, independently of systolic stretch
but failed to compensate adequately for tethering to prevent
MR.64 Management of severe ischaemic MR remains difﬁcult
with disappointing early and intermediate-term surgical results
of valve repair. Posterior leaﬂet extension with annuloplasty of
the mitral valve for severe type IIIb ischaemic regurgitationhas been suggested to provide good early and intermediate-
term competence of the mitral valve and functional status.65
In an experimental model, the papillary muscle tips in six adult
sheep were retracted apically, short of producing MR––thus
replicating the effects of tethering without confounding MI
or turbulence. At 60 days, total diastolic mitral leaﬂet area
increased by 17% and stretched mitral valves were 2.8 times
thicker than normal with an increased spongiosa layer. Cellu-
lar changes suggest a reactivation of embryonic developmental
pathways.66 It has been shown that mitral tenting leading to
functional MR is mainly determined by tethering (displace-
ment of papillary muscles) and pushing forces (increased left
atrial pressure), independently of ventricular function, ﬁndings
that emphasise the central role of left ventricular preload as a
key determinant of functional MR.67 In patients with idio-
pathic dilated cardiomyopathy who underwent annuloplasty
for functional MR, the postoperative distal mitral anterior
leaﬂet angle was the major determinant of recurrent functional
MR. The preoperative distal mitral anterior leaﬂet angle was
the best predictor of MR recurrence. Since posterior leaﬂet
tethering is invariable after mitral annuloplasty, postoperative
mitral competence is highly dependent on distal anterior leaﬂet
mobility.68 A strong association between pre-existing hyper-
tension and idiopathic mitral chordae tendineae rupture was
described. However, it remains unclear whether prevention
by hypertension control is feasible.698. Tricuspid regurgitation
The tricuspid valve is often called the forgotten valve, partly
because data concerning the optimal timing of surgery in tri-
cuspid regurgitation (TR) are limited.
During inspiration, a large increase in effective regurgitant
oriﬁce causes a notable increase in tricuspid regurgitant vol-
ume, despite a decline in regurgitant gradient. Effective regur-
gitant oriﬁce changes are independently linked to inspiratory
annular enlargement (decreased valvular coverage) and to
inspiratory right ventricular (RV) shape widening with
increased valvular tenting. These physiological insights are
important for the clinical evaluation of the severity of
TR.70 Severe TR, constrictive pericarditis and restrictive car-
diomyopathy can all present with signs and symptoms of
right heart failure and similar haemodynamic ﬁndings of ele-
vation and equalisation of diastolic pressures at catheterisa-
tion. The haemodynamic ﬁndings at cardiac catheterisation
in patients with severe, symptomatic TR are similar to those
of constrictive pericarditis. Careful analysis of the relation-
ship of the LV and RV diastolic pressures during respiration
can help differentiate between the two entities. During inspi-
ration, the difference between the LV and RV diastolic pres-
sures widens in patients with TR but narrows in those with
constrictive pericarditis.71 Of 69 consecutive patients under-
going surgery for isolated severe TR, seven (10.1%) died be-
fore discharge. Of the remaining 62 patients, three died
during follow-up and eight were readmitted owing to cardio-
vascular problems. RV end-systolic area (p= 0.006) and hae-
moglobin level (p< 0.001) were independent predictors of
event-free survival. When early postoperative echocardiogra-
phy variables were included, early postoperative RV frac-
tional area change provided additional information for
predicting long-term clinical events following corrective TR
8 R. Rosenheksurgery.72 The overall incidence of late signiﬁcant TR after
successful left-sided valve surgery was 7.7% (49/638). Age,
female gender, rheumatic aetiology, atrial ﬁbrillation and
peak pressure gradient of TR at follow-up were independent
factors associated with the development of late signiﬁcant
TR. Patients who developed late signiﬁcant TR showed a sig-
niﬁcantly lower 8-year clinical event-free survival rate (76%
vs 91%, p< 0.001).73 After tricuspid annuloplasty, tenting
angles of the three leaﬂets increase, whereas the annulus
diameter decreases. Presurgical tenting volume and antero-
posterior tricuspid annulus diameter are independent predic-
tors of residual TR severity, and may help to identify
patients at high risk for severe residual TR for whom tricus-
pid valve replacement may be considered.74 Tricuspid valve
replacement for severe TR can be performed with an accept-
able operative mortality if patients undergo surgery before
the onset of advanced heart failure symptoms. Late mortality
is associated with a high preoperative Charlson index, short
right index of myocardial performance ratio and advanced
New York Heart Association class.75
9. Risk of non-cardiac surgery
In a prospective cohort of 2054 patients undergoing elective
major non-cardiac surgery, high preoperative NT-proBNP or
C reactive protein were strong, independent predictors of
peri-operative major cardiovascular events (MI, pulmonary
oedema or cardiovascular death) in non-cardiac surgery. The
relative event-risk of highest versus lowest quartile was 5.2
for NT-proBNP (p< 0.001) and 3.7 for C reactive protein
(p< 0.001). The predictive power of the current clinical risk
evaluation system might be strengthened by the application
of these biomarkers.7610. Endocarditis
The high mortality of patients with endocarditis makes it an
important focus of continuing clinical research. Blood cul-
ture-negative early prosthetic valve endocarditis exhibits spe-
ciﬁc aetiologies, and fungi are the most common pathogens
identiﬁed. They should be investigated by molecular methods
on surgical specimens and an antifungal drug might be added
to the empirical treatment.77 Almost 50% of cases of coagu-
lase-negative staphylococcal prosthetic valve endocarditis oc-
cur between and 365 days after prosthetic valve implantation
and are associated with a high rate of methicillin resistance
and signiﬁcant valvular complications.78 Increasing age is
associated with less valvular impairment (insufﬁciency and
perforation) and a more favourable microbiological proﬁle
in patients with left-sided infective endocarditis. However,
the therapeutic approach differs depending on patient age be-
cause of the growing proportion of older patients who re-
ceive only medical treatment. Clinical course and hospital
prognosis are worse in older patients because of an increased
surgical mortality.79 Three independent risk factors obtained
within 72 h of admission for left-sided infective endocarditis
(Staphylococcus aureus, heart failure and periannular compli-
cations) predict in-hospital mortality or the need for urgent
surgery.80 Bicuspid aortic valve infective endo-carditis ac-
counts for 16% of cases of deﬁnite native aortic valve endo-
carditis and is associated with a perivalvular aortic abscess inhalf of the cases. The presence of a bicuspid aortic valve
(HR= 3.79, p< 0.001) is independently predictive of ab-
scess formation, and early surgery is often required.81 There
is now evidence that preoperative coronary angiography can
be performed with low risk in selected patients with aortic
valve endocarditis. A recent study reported no embolic
events, no increase in in-hospital mortality (p= 0.80) and
no worsening of renal function (p= 0.93).82 By performing
preoperative coronary angiography in patients with cardio-
vascular risk factors, those with signiﬁcant coronary disease
can be considered for bypass at the time of valve surgery.
In a multinational cohort of 1552 patients with native valve
endocarditis, early surgery was associated with a signiﬁcant
reduction in mortality compared with medical treatment
(12.1% vs 20.7%).83 Strategies of early surgery within 7 days,
at the discretion of the attending doctor, and of conventional
management in patients with left-sided native-valve were
compared in another study. During the initial hospitalisation,
there were no embolic events and two in-hospital deaths in
the surgical group (n= 64) and 14 embolic events and two
in-hospital deaths in the conventional group (n= 68). The
5-year event-free survival rate was signiﬁcantly better in the
surgical group (93 ± 3%) than in the conventional group
(73 ± 5%, p= 0.0016).84 Although the timing of surgery
was not randomly allocated, the data suggest that early sur-
gery, when feasible, may offer important advantages to the
patient.11. Valve surgery
11.1. Ross procedure
The controversy surrounding the Ross procedure is high-
lighted by four studies. In a randomised study 216 patients re-
ceived either an autograft or a homograft aortic root
replacement. At 10 years, four patients in the autograft group
and 15 in the homograft group died. Actuarial survival at
10 years was 97% in the autograft group versus 83% in the
homograft group.85 MRI of 45 patients at a median interval
of 8 years postoperatively demonstrated minor autograft and
homograft dysfunction in the majority of cases, associated
with good ventricular function and exercise capacity.86 An-
other study compared the outcome of the Ross procedure
(918 patients) with that of 406 mechanical valve recipients un-
der optimal self-management anticoagulation treatment; there
was no late survival difference in the ﬁrst postoperative decade
between the two groups. Survival in these selected young adult
patients closely resembles that of the general population, pos-
sibly as a result of optimised anticoagulation self-management,
timing of surgery and patient selection.87 A less optimistic pic-
ture was depicted by a study emphasising the broad spectrum
of complex reoperations that may be required relatively often
after the Ross procedure. The four most common indications
for reoperation (n= 56) were isolated autograft (neoaortic)
regurgitation in 20%, isolated pulmonary conduit regurgita-
tion/stenosis in 16%, combined autograft regurgitation/dilata-
tion in 14%, and combined auto-graft regurgitation and
pulmonary conduit regurgitation/stenosis in 11%. Patients
and family members considering the procedure should be in-
formed of the potential for associated morbidity should reop-
eration be necessary.88
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replacement
A 6 min walk test was found to be safe and feasible to carry
out in patients with severe AS before AVR, and provides
potentially important functional and prognostic information
for clinical assessment and the Euroscore risk score. At
12 months, the rate of death, MI or stroke was 13% in patients
walking <300 m as compared with 4% in those who walked
P300 m (p= 0.017).89 Physical quality of life 1 year after
valve surgery was predicted by baseline physical quality of
life and walk performance. Postoperative mental quality of life
was predicted by depression, baseline mental quality of life and
age, with age having a positive effect, suggesting that treating
depression and modifying negative illness beliefs preopera-
tively, may improve outcome.90 Women referred for AVR
were found to be older and more symptomatic. Although oper-
ative and long-term mortality were not increased, women re-
mained in a more symptomatic stage.91 Patients undergoing
renal transplantation requiring valve replacement have high
mortality rates (approximately 20%/year). Two-year survival
estimates were comparable for patients receiving a tissue valve
(61.5%) or a non-tissue-valve (59.5%, p= 0.30).92
11.3. Impact of age on valve surgery
Patients aged 55–70 years undergoing AVR either with
mechanical or bioprosthetic valves had similar 13-year rates
of survival, thromboembolism, bleeding, endocarditis and ma-
jor adverse prosthesis-related events. However, patients with
bioprosthetic valves had a signiﬁcantly higher risk of valve fail-
ure and reoperation.93 Using microsimulation of survival and
valve-related outcomes from 5470 AVR procedures, it was
found that bioprostheses may be implanted selectively in pa-
tients as young as 56 without signiﬁcant adverse effects on life
expectancy, although event-free survival remains signiﬁcantly
lower with bioprostheses for patients up to age of 63.94
Increasing numbers of the very elderly are undergoing AVR
procedures. Late survival of 2890 consecutive elderly patients
(P70 years) who underwent AVR was inﬂuenced by age and
preoperative comorbidities; the 33% in the lowest risk tertile
had an overall survival similar to that of the age- and sex-
matched general population. Structural deterioration of aortic
bioprostheses was rare and there was no conclusive evidence
that valve type affected survival in these patients.95 Also in
octogenarians, survival after AVR is favourable even with con-
comitant bypass surgery and more than half of the patients
survive for more than 6 years after their surgery. Median sur-
vival for patients under-going isolated AVR was 6.8 years for
those aged 80–84 years (n= 419) and 6.2 years for those aged
P85 years (n= 156), similar to the life expectancy of the gen-
eral population.96
11.4. Patient-prosthesis-mismatch
Patient-prosthesis-mismatch (PPM) was identiﬁed in 40% of
645 patients after AVR in a study in which indexed effective
oriﬁce area was obtained by postoperative echocardiography
and modelled as a continuous variable. After a median fol-
low-up of 2.35 years, 92.1% of the patients were alive. Cardiac
death among patients with a smaller indexed effective oriﬁcearea was signiﬁcantly increased (HR= 0.32, p= 0.022).97
Among 2576 patients who survived AVR and after adjustment
for other risk factors, severe PPM was associated with in-
creased late overall mortality (HR= 1.38; p= 0.03) and car-
diovascular mortality (HR= 1.63; p= 0.0006). Moderate
PPM was a predictor of mortality in patients with LV ejection
fraction <50% (HR= 1.21; p= 0.01), but not in patients
with preserved LV function.98 The presence of PPM after
AVR attenuates postoperative mitral regurgitation changes,
mainly in patients with organic mitral regurgitation.99 In 564
patients receiving an aortic valve bioprosthesis, structural
valve deterioration was diagnosed in 40 patients (7%). Steno-
sis-type structural valve deterioration (n= 24) was found to be
an early, PPM-related, and thus preventable, phenomenon.
Regurgitation-type structural valve deterioration (n= 16) is
a time-dependent, non-speciﬁc wear of bioprosthetic valves,
which is not related to PPM.100 In a multicentre series of
1006 mechanical and bioprosthetic mitral valves, PPM was
not associated with worse early outcomes or worse mid-term
survival.10111.5. Mitral valve surgery
Elective mitral valve (MV) repair can be performed with a low
operative mortality and good long-term outcomes in selected
octogenarians with degenerative mitral disease, and is associ-
ated with better long-term survival than mitral replacement.
Overall 90-day mortality of consecutive octogenarians who
underwent MV repair was signiﬁcantly lower (18.9%) than
for MV replacement (31.6%). Adjusted 1-, 3- and 5-year sur-
vival for patients undergoing MV repair was 71 ± 3%,
61 ± 4% and 59 ± 4%, respectively, compared with
56 ± 5%, 50 ± 6% and 45 ± 6% for patients undergoing
MV replacement (p= 0.046). The survival beneﬁt associated
with surgery for non-degenerative disease is more
questionable.102
Of 402 patients with atrial ﬁbrillation-associated MV dis-
ease who underwent MV replacement with a mechanical pros-
thesis, 159 underwent a concomitant Maze procedure. At a
median follow-up of 63.1 months, patients who had undergone
the Maze procedure were at signiﬁcantly lower risk of throm-
boembolic events (HR= 0.26; p= 0.041) and were at compa-
rable risk of death and cardiac death as patients who
underwent MV replacement alone.103
In 370 patients with ischaemic MR after adjusting for other
risk factors and propensity score, the type of procedure (MV
repair versus MV replacement) was not an independent predic-
tor of either operative or overall mortality.104 One hundred
and thirty-ﬁve patients with ischaemic heart disease and mod-
erate ischaemic MR underwent isolated coronary artery by-
pass graft surgery. At 1 year, 57 patients had no or mild
ischaemic MR, whereas 64 patients had failed to improve.
Large extent (P5 segments) of viable myocardium
(OR= 1.45; p< 0.001) and absence (<60 ms) of dyssynchro-
ny (OR= 1.49; p< 0.001) were independently associated
with improvement in ischaemic MR.105
Combined mitral and tricuspid valve repair in rheumatic
disease showed satisfactory early results in 153 consecutive pa-
tients (mean age 46 years) who underwent combined mitral
and tricuspid valve repair for rheumatic disease. However,
long-term results were poor because of high mortality and a
10 R. Rosenhekhigh number of valve-related reoperations. Survival-rate was
74.4% at 10 years and 57.0% at 15 years. At 20 years, the rate
of freedom from reoperation was 48.5%.106
11.6. Anticoagulation
Despite the use of intravenous unfractionated heparin, the rate
of early thromboembolism in a series of 300 consecutive
mechanical valve replacements remained signiﬁcant. Early
thromboembolism within 30 days of surgery occurred in 22 pa-
tients (14.8%) after a mitral or double mechanical valve
replacement and in two patients (1.3%) after an aortic
mechanical valve replacement (p= 0.005). Inappropriate anti-
coagulation on day 3 was signiﬁcantly associated with early
thromboembolism, suggesting that early effective anticoagula-
tion is required after mitral mechanical valve replacement.107
11.7. Prosthetic valve thrombosis
A randomised controlled trial comparing an accelerated infu-
sion with the conventional infusion of streptokinase was per-
formed in 120 patients with a ﬁrst episode of left-sided
prosthetic valve thrombosis, recruited over a 2.5-year period
at a single centre in India. The large patient number underlines
the massive burden of prosthetic valve thrombosis in develop-
ing countries. Fibrinolytic therapy with streptokinase is less
efﬁcacious than previously believed, with a complete clinical
response in 70 of 120 patients. The accelerated streptokinase
infusion is no better than standard infusion for left-sided pros-
thetic valve thrombosis.10812. Transcatheter aortic valve implantation
12.1. Patient selection
Objective parameters to assess interventional risk and thus to
identify patients at high risk who would beneﬁt from percuta-
neous procedures are needed. For this, reliable risk scores that
predict surgical mortality would be helpful. While the Euro-
SCORE still successfully discriminates high-risk patients
undergoing surgical aortic valve replacement, it has become
increasingly uncalibrated with absolute risk, resulting in
over-estimation of 30-day mortality.109 The limitations of risk
scores are also commented upon in a recent ESC position pa-
per on risk assessment before interventions in patients with
valvular disease.110
12.2. Imaging of the aortic annulus and of transcatheter aortic
valve deployment
Adequate sizing of the aortic annulus is essential in order to
assess the suitability of a patient for a transcatheter aortic
valve implantation (TAVI) procedure and the choice of the
prosthesis size. By CT an ellipsoid shape of the aortic valve
annulus with a larger coronal than sagittal diameter
(25.1 ± 2.4 vs 22.9 ± 2.0 mm, p< 0.001) was measured.111
2D imaging techniques underestimate aortic annulus diameters
and 3D imaging techniques are now recommended for this
purpose. 3D trans-oesophageal echocardiography (TOE) pro-
vides measurements of aortic annulus diameters similar tothose obtained by CT.112 While measurements using transtho-
racic echocardiography, TOE and CT are close but not identi-
cal, a strategy based on TOE measurements provides good
clinical results.113 The presence of LV dysfunction, male gen-
der and larger body surface area are independent determinants
of a larger aortic annular diameter.114 By CT, incomplete and
non-uniform expansion of the CoreValve frame can be identi-
ﬁed: undersizing and incomplete apposition is commonly pres-
ent.115 Non-circular deployment of the pros-thesis is found in
14% of patients. Moderate postprocedural aortic regurgitation
is seen in 11% patients and is associated with larger aortic
valve annulus, more calciﬁed native valves and less favourable
prosthesis deployment.111
12.3. Establishing a transcatheter aortic valve implantation
programme
To provide consistency across studies that can facilitate the
evaluation of this new catheter-based treatment, and improve
the quality of clinical research, the Valve Academic Research
Consortium proposed standardised consensus deﬁnitions for
important clinical end points in TAVI investigations.116 Retro-
spective examination of adherence to patient selection criteria
identiﬁed an ‘‘off-label’’ use of TAVI beyond pre-market label
indications in 42 of 63 patients.117 This study highlights the
challenges encountered in the rollout phase of a new technol-
ogy. The ability to offer either transfemoral or transapical aor-
tic valve implantation, using a standardised approach, with the
transfemoral approach as the ﬁrst option, may expand the
scope of the treatment of AS in high-risk patients and provide
satisfactory 1-year results.118 Introduction of a TAVI service
does not appear to have a negative effect on conventional sur-
gical activity. One study reported a 37% increase in surgical
AVR in the 2 years after introduction of TAVI in a dedicated
centre, compared with an 8% increase nationally (p<
0.001).119
12.4. Feasibility of transcatheter aortic valve implantation
An early single-centre experience established the feasibility of
TAVI, both by the transfemoral approach (n= 168), with a
success rate of 94.1% and 1-year survival of 74%,120 and by
the transapical approach (n= 100), with a success rate of
97% and 1-year survival of 73%.121 Data for an extended fol-
low-up period of 3 years have been reported, and no cases of
structural valvular deterioration, stent fracture, deformation,
or valve migration occurred.122
12.5. Procedural outcome of transcatheter aortic valve
implantation: registries and randomised trials
Patients with severe AS, considered unsuitable candidates for
surgery (n= 358), were randomly assigned to standard treat-
ment (including balloon aortic valvuloplasty) or transfemoral
TAVI using the Edwards SAPIEN valve in the PARTNER
B trial. TAVI, as compared with standard treatment, signiﬁ-
cantly reduced the rates of death from any cause (30.7% vs
50.7%), the composite end point of death from any cause or
repeat hospitalisation (42.5% vs 71.6%) and cardiac symp-
toms, despite a higher incidence of major strokes (5.0% vs
1.1%) and major vascular events (16.2% vs 1.1%).123 This
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severe symptomatic AS. The PARTNER A trial randomised
699 high-risk patients with severe AS to undergo TAVI or sur-
gical AVR. Transcatheter and surgical procedures for AVR
were associated with similar rates of survival at 1 year
(24.2% vs 26.8%, respectively), although there were important
differences in periprocedural risks, with vascular complications
more common in the TAVI group (11.0% vs 3.2%, p< 0.001)
and more frequent major bleeding and new-onset atrial ﬁbril-
lation with surgery.124 One-year survival in the SOURCE reg-
istry (n= 1038) was 76.1% (72.1% for transapical and 81.1%
for transfemoral TAVI). Interestingly, causes of death were
mainly non-cardiac in 49.2% (cardiac in 25.1%, and unknown
in 25.7%) with pulmonary complications (23.9%), renal failure
(12.5%), cancer (11.4%) and stroke (10.2%) as the most com-
mon non-cardiac causes of death.125 These data reﬂect the
importance of associated comorbidities. Several other multi-
centre registries (including the PARTNER EU registry, the
German TAVI registry, the French FRANCE registry, an Ital-
ian and a Canadian registry) have conﬁrmed the feasibility of
the procedure in high-risk or unoperable patients with AS with
good procedural success, haemodynamic results and mid-term
outcomes.126–131
12.6. Speciﬁc predictors of outcome for transcatheter aortic
valve implantation
Mean transprosthetic gradients were lower for TAVI
(10 ± 4 mm Hg) than for stented (13 ± 5 mm Hg) and stent-
less (14 ± 6 mm Hg) bioprostheses (p< 0.001). Severe PPM
was signiﬁcantly lower with TAVI (6%) than with a biopros-
thesis (24%; p= 0.007).132 TAVI can be successfully carried
out in most patients (34/35) with a small aortic annulus
diameter <20 mm, with severe PPM occurring in two pa-
tients only, and gradients remaining low in the other pa-
tients.133 It may also provide an interesting alternative to
AVR in patients with depressed LV systolic function, where
it is found to be associated with better LVEF recovery than
conventional AVR (change in LVEF 14 ± 15% vs 7 ± 11%;
p= 0.005), although these patients were older and had more
signiﬁcant comorbidities. At 1 year, 58% of TAVI patients
had a normalisation of LVEF (>50%) as opposed to 20%
in the AVR group.134 Pre-procedural functional performance
status (assessed by the Karnofsky index) predicts the in-hos-
pital procedural success rates and MI and stroke rates after
TAVI.135 Thirty days after TAVI quality of life and 6 min
walk distance improved signiﬁcantly while BNP levels de-
clined.136 Acute kidney injury occurring in 11.7% of patients
after TAVI, is associated with a greater than fourfold in-
crease in the risk of postoperative mortality. Hypertension,
chronic obstructive pulmonary disease and blood transfusion
are predictive factors of acute kidney injury.137 TAVI was
systematically associated with some degree of myocardial in-
jury in the majority of patients. The greater degree of myo-
cardial injury seen with the transapical approach and
baseline renal dysfunction is associated with less improve-
ment in LVEF and a greater cardiac mortality at follow-
up.138 Signiﬁcant AR was reported to occur in 17.2% of
patients and is associated with signiﬁcantly higher in-hospital
death rates (15.1% vs 6.7%), rates of low cardiac output and
respiratory failure.139 For the CoreValve a greater likelihoodof signiﬁcant AR was found with a greater angle of LV out-
ﬂow tract to ascending aorta (OR = 1.24, p= 0.001).140
New cerebral ischaemic lesions can be detected by diffu-
sion-weighted MRI in between 68% and 84% of patients
after TAVI.141–143 These lesions were usually multiple (1–19
per patient) and dispersed in both hemispheres in a pattern
suggesting cerebral embolisation. These foci were not associ-
ated with apparent neurological events or measurable deteri-
oration of neurocognitive function. The rate of major stroke
was in the range of 3.3–3.8%.124,141,4313. Transcatheter valve in a valve implantation
The concept of a valve in valve implantation in a degene-
rated aortic bioprosthesis was successful in 24 patients, with
a decline of mean transaortic gradient from 45.4 ± 14.8 to
10.1 ± 4.2 mm Hg. Major adverse cerebrovascular and
cardiac event rates were 0% and 14.1%, at 30 days and
12 months, respectively.144 Valve-in-valve implantations was
also performed in 24 high-risk patients with bioprostheses in
different positions (aortic, n= 10; mitral, n= 7; pulmonary,
n= 6; or tricuspid, n= 1). Implantation was successful, with
immediate restoration of satisfactory valve function in all but
one patient. Thirty-day mortality was 4.2%. Mortality was
related primarily to inexperience of the surgeon in this high-
risk procedure.14514. Transcatheter pulmonary valve implantation
Transcatheter pulmonary valve implantation of the Melody
valve was shown to be feasible in three series including 14,
102 and 136 patients with dysfunctional right ventricular out-
ﬂow tract conduits, respectively.146,148One death due to com-
pression of the left coronary artery147 and one death from
intracranial haemorrhage after coronary artery dissection oc-
curred.148 The studies consistently showed a signiﬁcant reduc-
tion of the right ventricular outﬂow tract gradient, a reduction
of right ventricular volume and of pulmonary regurgitation.
Freedom from Melody valve dysfunction or reintervention
was 93.5 ± 2.4% at 1 year. A higher right ventricular outﬂow
tract gradient at discharge (p= 0.003) and younger age
(p= 0.01) were associated with shorter freedom from dys-
function.148 The incidence of stent fractures was 5%.147 Pre-
stenting with a bare metal stent is associated with a lower risk
of developing percutaneous pulmonary valve implantation
stent fractures (HR = 0.35, p= 0.024).149 While short-term
follow-up data are encouraging, longer-term information is re-
quired to determine if this form of palliation has a signiﬁcant
impact on management strategies.15. Transcatheter tricuspid valve implantation
The ﬁrst human experience of successful percutaneous tricus-
pid valve implantation (Melody valve) in 15 patients with sig-
niﬁcant stenosis and/or regurgitation of a bioprosthetic
tricuspid valve or a right atrium-to-right ventricle conduit
was reported with a reduction of the mean tricuspid gradient
from 12.9 to 3.9 mm Hg (p< 0.01) and only mild or no resid-
ual regurgitation.150
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The challenges when implementing new techniques include pa-
tient selection, an adequate setting, and continuous evaluation,
and are well summarised by the NICE guidelines for percuta-
neous mitral valve repair.151 After the initial EVEREST Trial,
which was a feasibility study performed in 23 patients,152 the
randomised EVEREST II Trial compared the outcome of per-
cutaneous implantation of a clip (the MitraClip) that grasps
and approximates the edges of the mitral leaﬂets to conven-
tional mitral valve surgery in 279 patients with moderate or se-
vere MR. At 12 months, the following end points were seen for
patients in the percutaneous-repair group and in the surgery
group, respectively: death, 6% in each group; surgery for mi-
tral-valve dysfunction, 20% versus 2%; and grade 3+ or 4+
MR, 21% versus 20%. At 12 months, both groups had im-
proved LV size, New York Heart Association functional class
and quality-of-life measures, as compared with baseline.153
From a haemodynamic perspective, successful MitraClip
implantation in 107 patients resulted in an immediate and sig-
niﬁcant improvement in forward stroke volume, cardiac out-
put and LV loading conditions. There was no evidence of a
low cardiac output state after MitraClip treatment for
MR.154 Histological evaluation of 67 explanted MitraClip de-
vices showed that mechanical integrity of the device was main-
tained. Four phases of physiological healing include platelet
and ﬁbrin deposition, inﬂammation, granulation tissue and, ﬁ-
nally, ﬁbrous encapsulation. At long term, device ﬁbrous
encapsulation with extension over adjacent mitral leaﬂets
and tissue bridge formation adds structural stability.155 The
feasibility of percutaneous mitral annuloplasty through the
coronary sinus with the CARILLON Mitral Contour System
was shown in 30 of 48 patients, with functional improvement
and a major adverse event rate of 13% at 30 days.156
17. Percutaneous balloon mitral valvuloplasty
An increasing preprocedural MR severity was associated with
reduced percutaneous balloon mitral valvuloplasty (PMV) suc-
cess in a large study that included 876 patients (no MR, 75%;
1+MR, 65%; 2+MR, 44%; p< 0.0001), increased in-hospi-
tal mortality (0.6% vs 2.8% vs 4.9%, respectively; p= 0.007).
Patients with moderate preprocedural MR, in particular,
appear to have suboptimal short- and long-term outcomes,
requiring careful monitoring and early referral for mitral valve
surgery, when appropriate.157 After successful PMV, left atrial
volume and percentage change of the left atrial volume
immediately after PMV emerged as independent predictors
of event-free survival together with age, pre-PMV tricuspid
regurgitation and post-PMV mitral valve area. Ten-year sur-
vival was 93% in patients with smaller left atria before PMV
(672 ml/m2), whereas it was only 60% in those with larger left
atria (>72 ml/m2).158 After successful PMV (n= 329) an
immediate post-PMV mitral valve area P1.8 cm2 predicted
both restenosis and clinical event-free survival.159
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